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ORIGINAL RESEARCH

Reversing the “Risk-Treatment Paradox” of Bleeding in Patients
Undergoing Percutaneous Coronary Intervention: Risk-Concordant
Use of Bleeding Avoidance Strategies Is Associated With Reduced
Bleeding and Lower Costs
Amit P. Amin, MD, MSc; Samantha Miller, RN; Brandon Rahn, MHA; Mary Caruso, RN; Andrew Pierce, MHA; Katrine Sorensen, MS; Howard
Kurz, MD; Alan Zajarias, MD; Richard Bach, MD; Jasvindar Singh, MD; John M. Lasala, MD, PhD; Hemant Kulkarni, MD; Patricia CrimminsReda, RN

Background-—Bleeding is a common, morbid, and costly complication of percutaneous coronary intervention. While bleeding
avoidance strategies (BAS) are effective, they are used paradoxically less in patients at high risk of bleeding. Whether a patientcentered approach to speciﬁcally increase the risk-concordant use of BAS and, thus, reverse the risk-treatment paradox is
associated with reduced bleeding and costs is unknown.
Methods and Results-—We implemented an intervention to reverse the bleeding risk-treatment paradox at Barnes-Jewish Hospital, St.
Louis, MO, and examined: (1) the temporal trends in BAS use and (2) the association of risk-concordant BAS use with bleeding and
hospital costs of percutaneous coronary intervention. Among 3519 percutaneous coronary interventions, there was a signiﬁcantly
increasing trend (P=0.002) in risk-concordant use of BAS. The bleeding incidence was 2% in the risk-concordant group versus 9% in the
risk-discordant group (absolute risk difference, 7%; number needed to treat, 14). Risk-concordant BAS use was associated with a 67%
(95% conﬁdence interval, 52–78%; P<0.001) reduction in the risk of bleeding and a $4738 (95% conﬁdence interval, 3353–6122;
P<0.001) reduction in per-patient percutaneous coronary intervention hospitalization costs (21.6% cost-savings).
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Conclusions-—In this study, patient-centered care directly aimed to make treatment-related decisions based on predicted risk of
bleeding, led to more risk-concordant use of BAS and reversal of the risk-treatment paradox. This, in turn, was associated with a
reduction in bleeding and hospitalization costs. Larger multicentered studies are needed to corroborate these results. As clinical
medicine moves toward personalization, both patients and hospitals can beneﬁt from a simple practice change that encourages
objectivity and mitigates variability in care. ( J Am Heart Assoc. 2018;7:e008551. DOI: 10.1161/JAHA.118.008551.)
Key Words: anticoagulant • bleeding • cost • percutaneous coronary intervention • radial artery catheter

B

leeding is the most common complication of the
percutaneous coronary intervention (PCI) procedure.1–4
Bleeding is life-threatening, morbid, and painful and increases
patients’ risks of short- and long-term mortality.2,5,6 Bleeding
occurs in 2% to >10% of the more than 600 000 patients who
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undergo PCI each year.2,3,5,6 Bleeding costs $12 000 per
episode; therefore, there are signiﬁcant health and economic
burdens for patients and for society at large.7–14 Although
many hospitals have high rates of bleeding, few hospitals have
systematically attempted to reduce bleeding to make PCI
safer and more inexpensive.
Bleeding after PCI is predictable and modiﬁable, and
validated risk-prediction models can accurately quantify a
patient’s risk before bleeding occurs.4,15,16 If bleeding risk is
known, a patient-centered approach that targets patients at
risk with effective bleeding avoidance strategies (BAS) can be
used, such as bivalirudin,17,18 radial access,1,19 and vascular
closure devices (VCDs).3 Frequently, patients at risk of
bleeding also have renal disease and calciﬁed vessels and
are perceived to have difﬁculties with BAS use. Therefore, BAS
are currently used inconsistently, particularly among patients
with the highest risk of bleeding, hence called the bleeding
risk-treatment paradox.3 A prior analysis by our group from
Journal of the American Heart Association
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What Is New?
• In patients undergoing percutaneous coronary intervention,
bleeding avoidance strategies are used paradoxically less in
patients at high risk of bleeding (the bleeding risk-treatment
paradox), but few studies have directly attempted to reverse
the bleeding risk-treatment paradox.
• We prospectively implemented a patient-centered approach
directly aimed to encourage risk-concordant use of bleeding
avoidance strategies to reverse the bleeding risk-treatment
paradox, which was associated with a 67% reduction in
bleeding with an absolute risk difference of 7%, a number
needed to treat of 14, and a $4738 per-patient reduction in
percutaneous coronary intervention hospitalization costs.

What Are the Clinical Implications?
• The bleeding risk-treatment paradox in patients undergoing
percutaneous coronary intervention is pervasive in the
United States. Our study demonstrates the feasibility and
need of reversing it to reduce bleeding nationally.
• By focusing on bleeding risk at the point-of-care, it was
feasible to impact the risk-treatment paradox and achieve
risk-concordant use of bleeding avoidance strategies, which,
in turn, was associated with large reductions in bleeding and
costs.
Downloaded from http://ahajournals.org by on January 9, 2019

national data for 1.5 million PCI procedures revealed a clear
risk-treatment paradox.3
There have been few efforts20,21 to reverse the bleeding
risk-treatment paradox. In spite of the observation over the
past few years that the use of transradial access demonstrates
an increasing trend,22 systematic risk-based use of BAS is far
from established and, in fact, demonstrates a large risktreatment paradox.23 Conceptually, a patient-centered
approach to speciﬁcally increase the risk-concordant use of
BAS and reverse the risk-treatment paradox to reduce bleeding
has not been examined. Furthermore, the impact of such riskconcordant BAS use on hospital costs has not been examined.
We, therefore, implemented a speciﬁc intervention to reverse
the risk-treatment paradox at Barnes-Jewish Hospital (BJH) in
St. Louis, MO, and examined: (1) the temporal trends in BAS
use and (2) the association of risk-concordant BAS use with
bleeding outcomes and hospital costs of PCI.

Methods
Patient-Centered Intervention
We implemented a patient-centered approach via a nurse-led
health information technology solution24,25 to translate a
bleeding risk-prediction model,4 to predict individualized
DOI: 10.1161/JAHA.118.008551

bleeding risk in the cardiac catheterization laboratory, to
explicitly bring bleeding risk to the physician’s attention via a
decision aid, and to encourage risk-concordant use of BAS for
patients at risk. Before the decision on choice of access and
anticoagulant use was made, the intraprocedural nurse
performed a mandatory “time-out” to include the predicted
bleeding risk from the decision aid, with a hard stop to not
proceed unless the bleeding risk was acknowledged by the
attending physician. Thus, the treatment decisions for BAS
made by the physician were based fully on the predicted risks
of bleeding.

Study Design and Implementation
This study was designed as a patient-centered, pre-post quasiexperimental design to investigate PCI bleeding outcomes and
BAS use from the years preceding the implementation
compared with those after the implementation. We implemented the patient-centered approach by a nurse-led, health
information technology solution, ePRISM, to translate NCDR
(National Cardiovascular Data Registry) CathPCI bleeding riskprediction model4 to generate personalized estimates of
bleeding risk, which were displayed as a decision aid in the
catheterization laboratory to inform physicians of each
patient’s personalized bleeding risk before PCI (Figure 1).
The decision aid encouraged physicians to use risk-concordant BAS, aligned with each patient’s personalized bleeding
risk (Figure 1). We also performed monthly audits and
feedback for peer-to-peer comparisons of physicians’ bleeding
rates and risk-concordant use of BAS, to align use of BAS with
patients’ bleeding risk.

Study Population
This study included 3519 PCIs (conducted in 3366 patients)
at BJH in St. Louis, MO, from July 2012 to September 2015.
We used BJH data from the NCDR CathPCI Registry. The
CathPCI Registry itself is cosponsored by the American
College of Cardiology and the Society for Cardiovascular
Angiography and Interventions, and has been used extensively
in the past.26 This registry evaluates characteristics, treatments, and outcomes of patients undergoing PCI and/or
diagnostic catheterization.26 Complete deﬁnitions for all
predeﬁned variables are available at the American College
of Cardiology’s NCDR website (http://cvquality.acc.org/en/
NCDR-Home/Registries/Hospital-Registries.aspx). The CathPCI Registry is available for numerous hospitals, but this study
was solely limited to BJH, where we implemented the patientcentered approach. The aforementioned, patient-centered
approach was instituted in May 2013. However, a period of
6 months was required for training and routine use of this
intervention. Therefore, our study tenure could be
Journal of the American Heart Association
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Figure 1. Decision aid used for encouraging risk-concordant
use of bleeding avoidance strategies. GFR indicates glomerular
ﬁltration rate.

conceptually divided into 2 phases: the years 2012–2013
represent the baseline scenario, while the years 2014–2015
represent the changes after the implementation was fully in
place. However, the adoption of this patient-centered
intervention was gradual and represented a continuum of
change in clinical practice over the study period. The study
was approved by Washington University’s institutional review
board, and no informed consent was required.

Predictors and Outcomes
BAS included procedural access through the radial artery,
bivalirudin administration, and use of VCDs. The preprocedural, predicted bleeding risk for each PCI was classiﬁed into 1
of 3 strata: low (<0.02), moderate (0.02–0.065), or high
(≥0.065). These thresholds corresponded to the categorization used by the NCDR CathPCI bleeding risk model.4 A riskconcordant approach to BAS use was deﬁned as no BAS use
for low predicted bleeding risk, but at least 1 BAS for the
DOI: 10.1161/JAHA.118.008551

Statistical Analysis
Continuous variables were described as means and SDs and
categorical variables were described as proportions. Comparison of continuous variables across categories of a dichotomous variable was performed using Student t test. Clinical
beneﬁt of the use of risk-concordant BAS was estimated as
absolute risk reduction, number needed to treat (deﬁned as
inverse of absolute risk reduction), and odds ratio. Independent association of risk concordance with outcomes was
determined using logistic regression model adjusting for the
predicted bleeding risk (obtained from several clinical variables from the CathPCI bleeding risk model4) and predicted
risk of mortality (obtained from several clinical variables from
the CathPCI mortality risk model27). Improvements in costs
were measured using cost differences between the riskconcordant and risk-discordant groups indexed to the riskdiscordant group and converted to a percent as follows: 1009
(CC CD)/CD, where CC and CD represent the average perpatient costs in the risk-concordant and risk-discordant
groups, respectively. Temporal trends were assessed using
calendar year as a predictor in logistic or linear regression
Journal of the American Heart Association
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moderate predicted bleeding risk, and 2 BAS for high
predicted bleeding risk.
The primary outcome of interest was post-PCI bleeding
deﬁned by NCDR CathPCI criteria as any of the following:
(1) bleeding event within 72 hours; (2) hemorrhagic stroke;
(3) tamponade; (4) post-PCI transfusion for patients with a
nonmissing preprocedure hemoglobin level of <8 g/dL; and
(5) absolute hemoglobin decrease from pre- to post-PCI of ≥3
g/dL with a nonmissing preprocedure hemoglobin of ≤16 g/
dL.26 A secondary outcome of interest was total operating
costs from the hospital’s perspective. The total operating
costs for a case were directly available (except for the last
quarter) from the ﬁnance department of BJH, which included
direct and indirect and ﬁxed and variable costs. Costs were
inﬂation-adjusted to the 2016 US dollar using the medical
consumer pricing index (https://www.bls.gov/cpi/). Since
the outcomes of bleeding and costs relate to the index PCI
procedure, the unit of all analyses is the PCI procedure and
not the individual patient.
Considering the observational nature of this work, adoption
of the patient-centered approach to encourage risk-concordant use of BAS yielded 2 post-facto comparative groups—a
group of patients in whom the BAS choices made were
concordant with the bleeding risk estimates as described
above (the risk-concordant group), and the remaining patients
were categorized as the risk-discordant group, reﬂecting a
risk-treatment paradox.3 This study is observational and
compares the outcomes and costs in the risk-concordant and
risk-discordant groups.
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Amin et al

Results
Study Participants
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Data for this study came from 3366 patients, of whom 145
(4.3%) underwent 2 PCIs and 8 (0.2%) underwent 3 PCIs during
the study period. Among the patients undergoing PCIs
(n=3519), the average age was 64 years, with 1116 (32%)
individuals in the octogenarian age group. Obesity (body mass
index >30 kg/m2, 43%), diabetes mellitus (44%), dyslipidemia
(88%), and hypertension (92%) were common and frequently
coexisted. There was a high proportion of chronic renal (30%)
and lung (22%) disease. The average left ventricular ejection
fraction was 52.1%, and 20% to 55% individuals had a
signiﬁcant history of heart failure, coronary artery disease,
myocardial infarction, peripheral artery disease, or previous
cardiac interventions. Furthermore, coronary disease of 2 of 3
major coronary vessels that often required 2 stents, with an
average 1.4 number of lesions, was common. Overall, 80% of
the PCIs used at least 1 BAS—the most common being the use
of a closure device with femoral access (65%) and bivalirudin
(41%) and the least common being radial access (12%).

Presence of Risk-Treatment Paradox
Comparison of the patient characteristics across the riskconcordant and risk-discordant groups is provided in Table 1.
The risk-treatment paradox was observed: risk-concordant
BAS use was lower in the patients with higher bleeding risk in
general. For example, in patients with diabetes mellitus,
chronic kidney disease, current dialysis, and history of heart
failure, myocardial infarction or peripheral arterial disease,
which all contributed to a higher bleeding risk, there was a
lower likelihood of risk-concordant BAS use. Of the 478
patients classiﬁed preprocedurally as having a low risk of
bleeding, 414 (86.6%) received at least 1 BAS, but a smaller
proportion of patients with moderate and high bleeding risk
(82.8% and 72.3%, respectively) received at least 1 BAS.
DOI: 10.1161/JAHA.118.008551

These ﬁndings underscore a risk-treatment paradox in BAS
use and emphasize the need for greater risk-concordant use
of BAS.

Inﬂuence of Risk-Concordant BAS Use on
Outcomes and Cost of PCI
We found that the incidence of bleeding events was 2% in the
risk-concordant versus 9% in the risk-discordant group, which
yielded an absolute 7% higher risk difference and a number
needed to treat of 14 (Table 2). In the univariable logistic
regression model, risk-concordant BAS use was associated
with bleeding events with an odds ratio of 0.20 (95%
conﬁdence interval [CI], 0.14–0.29; P<0.001). When adjusted
for the risk of bleeding and the risk of mortality, riskconcordant BAS use was associated with bleeding events with
an odds ratio of 0.33 (95% CI, 0.22–0.48, P<0.001), implying
a 67% relative risk reduction (95% CI, 52–78%) when BAS
were aligned with risk of bleeding (model 3, Table 2). This full
model predicted a bleeding event with an accuracy of 82%.
These ﬁndings indicate a strong and independent association
of risk-concordant BAS use with the outcomes of PCI.
Similarly, when we compared the total operating perpatient costs from a hospital perspective, we observed that
the risk-concordant use of BAS was associated with a $4738
(95% CI, $3353–$6122; P<0.001) reduction in hospital costs
that translated to a cost-savings of 21.6% (Table 2). Thus,
risk-concordant use of BAS was strongly and independently
associated with improvements in both costs and bleeding
outcomes.
We then examined whether the increased costs associated
with the use of bivalirudin and VCDs among femoral cases and
bivalirudin alone among radial cases was offset by the costssavings. The cost beneﬁt associated with speciﬁc combinations of the BAS is presented in Table 3. We found that in
patients with moderate and high predicted risk of bleeding, all
BAS—singly or in combination—offered signiﬁcant costsavings.

Temporal Trends in BAS Use
After we implemented the patient-centered approach for
risk-concordant use of BAS, there was a gradual increase in
the risk-aligned use of BAS. We tested the hypothesis that
the increasing acceptance of risk-concordant BAS use over
time is directly proportional to an improvement in bleeding
event rates and total operating costs. We observed that the
proportion of patients who received risk-concordant BAS
use increased over time (Figure 2A). It was 49% in the
calendar year 2012, 46% in the year 2013, 53% in the year
2014, and 56% in the calendar year 2015 (P value for trend
<0.001). Concomitantly, the bleeding incidence rate
Journal of the American Heart Association
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models for categorical or continuous dependent variables,
respectively. The inﬂuence of the patient-centered approach
on study outcomes was examined by comparing the riskconcordant BAS use, hospitalization costs, and bleeding rates
before and after the implementation using chi-square test for
categorical variables and Mann–Whitney test for continuous
variables. Statistical signiﬁcance was estimated at a type I
error rate of 0.05. All analyses were conducted using Stata
12.0 statistical package (StataCorp). The analytic methods
and study materials will be made available to other
researchers upon request for purposes of reproducing the
results or replicating the procedure. The data will not be made
publicly available as they belong to BJH.
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Table 1. Patient and Procedural Characteristics
Characteristic

Risk-Concordant BAS (n=1866)

Risk-Discordant BAS (n=1653)

P Value

Age, meanSD, y

64.312.0

64.612.6

0.459

Women, No. (%)

563 (30.2)

572 (34.6)

0.005

Body mass index, meanSD

30.56.51

29.87.62

0.002

Diabetes mellitus, No. (%)

794 (42.6)

752 (45.5)

0.079

Patient characteristics

Dyslipidemia, No. (%)

1654 (88.6)

1440 (87.1)

0.166

Hypertension, No. (%)

1707 (91.5)

1511 (91.4)

0.941

Chronic lung disease, No. (%)

396 (21.2)

374 (22.6)

0.315

Chronic kidney disease (GFR ≤60) (N=3506), No. (%)

369 (19.8)

577 (35.1)

<0.001

Current dialysis, No. (%)

29 (1.6)

120 (7.3)

<0.001

Pre-PCI ejection fraction, meanSD (N=2375)

53.613.5

50.315.0

<0.001

Prior coronary artery bypass graft surgery, No. (%)

519 (27.8)

420 (25.4)

0.107

Prior cerebrovascular disease, No. (%)

375 (20.1)

362 (21.9)

0.190

Prior heart failure, No. (%)

699 (37.5)

692 (41.9)

0.008

Prior myocardial infarction, No. (%)

923 (49.5)

887 (53.6)

0.013

Prior peripheral arterial disease, No. (%)

314 (16.8)

397 (24.0)

<0.001

Prior PCI, No. (%)

1024 (54.9)

915 (55.4)

0.776

Procedural characteristics

Downloaded from http://ahajournals.org by on January 9, 2019

No. of lesions, meanSD

1.380.66

1.450.74

0.002

Total lesion length, meanSD

37.725.8

39.726.4

0.023

No. of diseased vessels, meanSD

1.790.83

1.820.83

0.319

No. of stents, meanSD

1.801.05

1.971.16

<0.001

0.00.0 (64)

1.430.49 (414)

BAS*
No. of BAS used by bleeding risk categories
Low risk (n=478), meanSD (No.†)
Moderate risk (n=1815), meanSD (No.

†)

1.370.48 (1503)

0.00.0 (312)

High risk (n=1226), meanSD (No.)†

2.000.0 (299)

0.630.48 (927)

Radial access, No. (%)

310 (16.6)

98 (5.93)

Bivalirudin, No. (%)

1066 (57.1)

353 (21.4)

Closure devices, No. (%)‡

1285 (82.6)

726 (46.7)

At least 1 BAS, No. (%)

1802 (96.6)

1001 (60.6)

*Since the deﬁnition of risk concordance directly uses information from bleeding avoidance strategies (BAS) use, no statistical hypotheses were tested for the variables in this group.
†
SD of 0 indicates that all values were identical for that category.
‡
Closure is only assessed for percutaneous coronary interventions (PCIs) with femoral access (n=3111).

decreased from 9.8% in the calendar year 2012, 6.5% in
the year 2013, 5.3% in the year 2014, and 3.8% in the
calendar year 2015 (P value for trend <0.001). Furthermore, the costs of PCI were $19 666 in 2012, $20 348 in
2013, $19 320 in 2014, and $17 836 in 2015 (P value for
trend <0.001).
We also compared the proportion of patients who received
risk-aligned use of BAS in 2012–2013 (before the implementation fully began) with that in 2014–2015 (during or after the
DOI: 10.1161/JAHA.118.008551

implementation). We observed a 6% increase in the use of BAS
(from 50% in 2012–2013 to 56% in 2014–2015, P=0.0004)
(Figure 2B). This increase was consistently associated with a
1.4% reduction in the incidence of bleeding (from 4.4% to 2012–
2013 to 3.0% in 2014–2015, P=0.0279) and a decrease in
hospitalization costs by $1429 per-patient (from $15 610 in
2012–2013 to $14 181 in 2014–2015, P<0.0001) (Figure 2B).
Together, these results suggest that an increasing proportion of risk-concordant BAS use may translate to improved
Journal of the American Heart Association
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Analysis

Result

Bleeding events in the riskconcordant BAS group, No. (%)

38 (2.0)

Bleeding events in the riskdiscordant BAS group, No. (%)

156 (9.4)

P value

<0.001

Absolute risk reduction, %

7.4

No. needed to treat

14

Discussion

Relative risk (95% CI, P value)*
Model 1: univariable

0.20 (0.14–0.29, <0.001)

Model 2: adjusted for
predicted bleeding risk

0.33 (0.22–0.48, <0.001)

Model 3: adjusted for predicted
bleeding and mortality risk

0.33 (0.22–0.48, <0.001)

Area under the ROC curve
for model 3 (95% CI)†

0.82 (0.79–0.85)

Total operating costs (2016 US$)
Risk-concordant BAS, mean (95% CI)
Risk-discordant BAS, mean (95% CI)

$19 449 to $17 219, representing an annual $2.41 million in
potential savings. In actuality, the average costs of PCI in the
earlier part of the implementation from June 2012 to
December 2013 were $20 114 per PCI for 1574 cases, while
the average costs of PCI in the later part of the implementation from January 2014 to September 2015 were $18 797
per PCI for 1604 cases, translating to $2.11 million in actual
accrued savings.

17 219 (16 375–18 064)
21 957 (20 837–23 077)

Cost-savings (average per-patient cost
reduction attributable to risk
concordance) (95% CI), 2016 US$

$4738 ($3353–$6122)

Cost-savings (95% CI), %

21.6 (15.8–26.9)

Downloaded from http://ahajournals.org by on January 9, 2019

BAS indicates bleeding avoidance strategies; CI, conﬁdence interval; ROC, receiver
operating characteristic.
*Relative risk of bleeding in the risk-concordant group as compared with the riskdiscordant group.
†
Predictive accuracy of the model.

costs and bleeding outcomes of PCI. Indeed, our results
project that if all the patients from BJH from 2012 through
2015 included in this study were to receive risk-concordant
use of BAS then the overall bleeding rates could have
decreased from the overall 5.5% to 2.1% and the per-patient
total operating costs could have decreased from the overall

This is the ﬁrst prospective observational study to directly
address reversal of the bleeding risk-treatment paradox via a
focused patient-centered intervention. Our study found that
the risk-treatment paradox was commonly observed. By
focusing on risk of bleeding at the point of care, it was
feasible to impact but also difﬁcult to fully reverse the risktreatment paradox. Nonetheless, even partial reductions in
the risk-treatment paradox, achieved by the risk-concordant
use of BAS, were associated with substantial reductions in the
incidence of bleeding and hospital costs. The association of
risk-concordant use of BAS, with reductions in the incidence
of bleeding and hospital costs was independent of bleeding
risk and mortality risk. Furthermore, an increasing trend in
risk-concordant use of BAS was associated with concomitant
reducing trends in the incidence of bleeding and hospital
costs.
The Institute of Medicine deﬁnes patient-centered care as
“care that is respectful of and responsive to individual patient
preferences, needs, and values,” ensuring that patient needs
and values guide all clinical decisions.28–31 The Institute of
Medicine has recognized patient-centered care as 1 of 6
major domains of healthcare quality.28–31 While the healthcare community widely recognizes the potential of health
information technology in enabling patient-centered care, we
have yet to see patient-centered care being used to improve
PCI outcomes in the catheterization laboratory—an area of
critical need, and a very large service area, where >600 000

Table 3. Cost-Savings Associated With Combinations of BAS
BAS Used
Radial

Bivalirudin

VCDs

No.

%

Cost-Savings (2016 US$)

No

No

No

652

21.44

Reference

No

No

Yes

1004

33.02

5108.15 ( 7301.25 to

2915.04)

No

Yes

No

344

11.31

1390.74 ( 4235.47 to 1454.00)

No

Yes

Yes

676

22.23

5896.44 ( 8272.16 to

3520.73)

Yes

No

No

182

5.98

4934.37 ( 8672.03 to

1196.71)

Yes

Yes

No

183

6.02

5074.00 ( 8821.30 to

1326.70)

BAS indicates bleeding avoidance strategies; VCDs, vascular closure devices.

DOI: 10.1161/JAHA.118.008551
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Table 2. Association of Risk-Concordant BAS Use With
Occurrence of Bleeding
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Figure 2. Trends in risk-concordant use of bleeding avoidance strategies (BAS), bleeding rates, and hospitalization costs. A, Quarterly
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estimates of risk-concordant BAS use, bleeding rates, and hospitalization costs. Dashed, color-coded lines represent the least squares
regression lines. B, Comparison of risk-concordant BAS use, bleeding rate, and hospitalization costs before (hollow bars) and after (solid bars)
implementation of the patient-centered approach. P, signiﬁcance values estimated using chi-square test for risk-concordant BAS use and
bleeding rates and using Mann–Whitney U test for hospitalization costs. Costs are shown as inﬂation-adjusted 2016 US$. The corresponding
regression equations are as follows: logit (proportion risk-concordant)=0.02759quarter 0.0727; logit (bleeding rate)= 0.06989quarter 2.8242; hospitalization cost= 250.239quarter+21 088.68. Q indicates quarter.

PCI procedures are performed annually in the United States
alone.
The presence of a risk-treatment paradox implies that care
in the catheterization laboratory is not aligned to the
predicted risk of bleeding. Frequently, BAS are used the least
for patients with the highest risk of bleeding, which we
observed in our hospital as well. A challenge to reversing the
risk-treatment paradox is that physician behavior may be
inﬂuenced by clinical notions rather than evidence-based
facts.32 For example, bleeding is considered an unpredictable
and unavoidable event and, hence, to date, there have been
no systematic or sustained efforts to reduce PCI-related
bleeding. Directly contradicting this notion is the fact that the
risk of bleeding is both predictable4 and modiﬁable2,3 and our
study demonstrates that bleeding is preventable by explicitly
accounting for the bleeding risk in decision-making and
reversing the risk treatment paradox.
It is important to note that our study is consistent with
prior studies demonstrating that it is difﬁcult to change
physician behavior.33 Physicians in the United States have
DOI: 10.1161/JAHA.118.008551

autonomy in decisions about care for patients, and thus their
decisions are signiﬁcant drivers of healthcare cost and
outcomes. In the era of alternate payment models, targeting
providers and physicians to improve the value of care is
anticipated. However, physician behavior is difﬁcult to
change.33 Despite explicitly targeting bleeding risk before a
case, the risk-concordant use of BAS was seen in only 57% of
patients in the year 2015—2 years after introducing it in
2013. Nonetheless, even this modest degree of change in
physician practice was associated with a marked reduction in
bleeding outcomes and cost. It is therefore both important
and required to use results from studies such as this to
highlight and encourage the use of evidence-based, objective
methods of bleeding management in PCI.
While bleeding is known to increase costs of care, this is
the ﬁrst report to show that a reduction in bleeding event
rates is also associated with a parallel reduction in costs. A
bleeding event costs $8000 to $12 000. By using BAS in a
risk-concordant manner, we observed a $4738 (95% CI,
3353–6122; P<0.001) reduction in per-patient PCI costs
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is urgently required. Larger and multicentered studies are
also needed to corroborate and generalize these results. As
clinical medicine inches toward personalization of care, both
the patient (through reduced rates of adverse outcomes) and
the hospitals (via substantial reduction in per-patient costs)
are likely to beneﬁt by a simple change of practice that
encourages objectivity and mitigates variability in care.

Study Limitations

Downloaded from http://ahajournals.org by on January 9, 2019

This study must be interpreted in light of some limitations. First,
our study is from a single hospital, which may limit its
generalizability. Nevertheless, it demonstrates an important
proof-of-concept that even a modest improvement in patientcentered care results in substantial improvements in outcomes
and costs. Since the risk-treatment paradox is pervasive in the
United States, our study demonstrates the feasibility and need
of reversing it to reduce bleeding. Second, our study is
observational in nature and the reduction in bleeding and costs
observed with patient-centered care should be interpreted as
an association and not causal in nature. For example, changes
in catheterization laboratory physician stafﬁng can also
inﬂuence the practice of BAS use and, hence, outcomes.
However, during this study period, there were no changes in
physician stafﬁng of our catheterization laboratories. Another
change that could potentially explain an increasing trend in
bivalirudin use is the availability of generic bivalirudin. However,
generic bivalirudin was approved by the Food and Drug
Administration in July 2015, which marked the end of our
study period and is unlikely to have impacted our results. Still,
the presence of other unknown confounders related to the
catheterization laboratory operation cannot be ruled out. Third,
while we studied a large number of PCIs, the rarity of the
bleeding event can inﬂuence the statistical power. We thus
derived post hoc power estimates and found that the large
bleeding incidence differential and cost differential provided a
statistical power in excess of 99% for our study. Fourth, we
used VCDs and bivalirudin as BAS and this is a controversial
issue. While VCDs have shown an association with reduced
bleeding using the NCDR CathPCI bleeding deﬁnition,3 other
studies have shown only modest beneﬁt, selective beneﬁt in
high-risk cases, or no beneﬁt at all.34,35 Last, the unit of
analysis was PCI and not patients. While some residual
correlation in the <5% patients who underwent >1 PCI can
theoretically inﬂuence the results, we believe that such an
inﬂuence would be minimal given that 91.4% of the PCIs in our
sample were contributed to by unique patients.

Conclusions
Patient-centered care that directly aims to make treatmentrelated decisions based on predicted probability of bleeding
DOI: 10.1161/JAHA.118.008551
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